MDSpire - Summary
From the Journals
Commentary & Perspectives

Prednisolone Linked to Metabolic Benefits

A randomized crossover trial found slower bone turnover and no safety differences compared with standard hydrocortisone regimens

Share

A randomized crossover trial indicates that low-dose prednisolone taken once daily may provide some cardiometabolic benefits compared to thrice-daily hydrocortisone for patients with adrenal insufficiency. Involving 46 participants, the study measured bone turnover and cardiometabolic outcomes over 120-day periods. Prednisolone showed a slower bone turnover and improvements in body weight and glycated hemoglobin, though no differences were noted in subjective health outcomes. Researchers stress that more extensive investigations are needed to assess long-term implications.

Original Source(s)

Prednisolone Linked to Metabolic Benefits

  • by Henry Thomas

  • April 1, 2026

Related Content

FDA Approves Lilly’s Foundayo Oral GLP-1 Pill

The newly approved therapy offers a noninjectable option that can be taken at any time of day without food or water restrictions.

PFAS Exposure Linked to Faster Epigenetic Aging 

Epigenetic clock analysis ties PFNA exposure to faster biological aging, particularly in men aged 50–64 

  • April 1, 2026

  • 2 min
Your Biological Age? It's in the Blood

Multi-marker model may refine risk prediction and preventive testing

  • April 1, 2026

  • 2 min